S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?

Zymeworks Stock Price, News & Analysis (NYSE:ZYME)

$9.10
+0.09 (+1.00%)
(As of 12/6/2023 ET)
Compare
Today's Range
$8.89
$9.30
50-Day Range
$6.18
$9.23
52-Week Range
$5.76
$10.80
Volume
321,637 shs
Average Volume
562,866 shs
Market Capitalization
$637 million
P/E Ratio
2.93
Dividend Yield
N/A
Price Target
$12.44

Zymeworks MarketRank™ Stock Analysis

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
36.8% Upside
$12.44 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Zymeworks in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.97) to ($1.21) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

630th out of 957 stocks

Pharmaceutical Preparations Industry

265th out of 399 stocks


ZYME stock logo

About Zymeworks Stock (NYSE:ZYME)

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

ZYME Stock Price History

ZYME Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Recap: Zymeworks Q3 Earnings
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Zymeworks Inc Registered Shs
Zymeworks Announces New Director Nominee
H.C. Wainwright Sticks to Its Hold Rating for Zymeworks (ZYME)
Zymeworks earnings: here's what Wall Street expects
Zymeworks (NYSE: ZYME)
Zymeworks Inc.: Zymeworks Appoints New Director
Zymeworks Appoints New Director
See More Headlines
Receive ZYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/05/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Previous Symbol
NASDAQ:ZYME
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.44
High Stock Price Target
$19.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+36.8%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$124.34 million
Pretax Margin
47.75%

Debt

Sales & Book Value

Annual Sales
$412.48 million
Cash Flow
$2.15 per share
Book Value
$7.82 per share

Miscellaneous

Free Float
69,148,000
Market Cap
$637 million
Optionable
Optionable
Beta
0.97
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Kenneth H. Galbraith C.A. (Age 60)
    CEO & Chairman of the Board
    Comp: $1.22M
  • Dr. Christopher Astle Ph.D. (Age 43)
    Senior VP & CFO
    Comp: $721.23k
  • Ms. Bijal Desai M.B.A.
    Executive Director of Corporate Finance, FP&A & Procurement
  • Mr. Mark Hollywood (Age 53)
    Executive VP and Head of Technical & Manufacturing Operations
  • Dr. Paul Moore Ph.D. (Age 56)
    Chief Scientific Officer
  • Jack W. Spinks
    Associate Director of Investor Relations
  • Mr. Daniel Dex J.D.
    Ph.D., Senior VP, Corporate Secretary & General Counsel
  • Diana Papove
    Senior Manager of Corporate Communications
  • Ms. Laura O'Connor
    Executive Director & Head of Global Human Resources
  • Dr. Jeffrey Smith M.D.
    Senior Vice President of Early-Stage Development














ZYME Stock Analysis - Frequently Asked Questions

Should I buy or sell Zymeworks stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZYME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYME, but not buy additional shares or sell existing shares.
View ZYME analyst ratings
or view top-rated stocks.

What is Zymeworks' stock price target for 2024?

7 equities research analysts have issued twelve-month price targets for Zymeworks' shares. Their ZYME share price targets range from $8.00 to $19.00. On average, they expect the company's stock price to reach $12.44 in the next year. This suggests a possible upside of 36.8% from the stock's current price.
View analysts price targets for ZYME
or view top-rated stocks among Wall Street analysts.

How have ZYME shares performed in 2023?

Zymeworks' stock was trading at $7.86 at the beginning of the year. Since then, ZYME shares have increased by 15.8% and is now trading at $9.10.
View the best growth stocks for 2023 here
.

When is Zymeworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our ZYME earnings forecast
.

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) posted its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.14. The business had revenue of $16.51 million for the quarter, compared to analyst estimates of $10.17 million. Zymeworks had a net margin of 44.47% and a trailing twelve-month return on equity of 44.62%.

What ETF holds Zymeworks' stock ?

Invesco Russell 2000 Dynamic Multifactor ETF holds 148,747 shares of ZYME stock, representing 0.32% of its portfolio.

What is Ali Tehrani's approval rating as Zymeworks' CEO?

9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a number of retail and institutional investors. Top institutional investors include Morgan Stanley (6.41%), Rubric Capital Management LP (3.79%), Rubric Capital Management LP (3.79%), Acadian Asset Management LLC (1.18%), AQR Capital Management LLC (1.14%) and Jupiter Asset Management Ltd. (0.70%). Insiders that own company stock include Ali Tehrani, Christopher Astle, Ecor1 Capital, Llc, James Priour, Kathryn O'driscoll, Neil A Klompas and Neil Josephson.
View institutional ownership trends
.

How do I buy shares of Zymeworks?

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:ZYME) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -